http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CORRECTING AND REPLACING: Aegon completes share buyback program
-
Aegon to divest last block of US life reinsurance business
-
Aegon to divest last block of US life reinsurance business
-
Aegon to divest last block of US life reinsurance business
-
Aegon to divest last block of US life reinsurance business
-
Aegon and Santander to expand successful partnership in Spain
-
Aegon and Santander to expand successful partnership in Spain
-
Aegon announces repurchase of shares to neutralize stock dividend
-
Aegon announces repurchase of shares to neutralize stock dividend
-
Aegon provides update on financial transformation and capital management
-
Aegon provides update on financial transformation and capital management
-
CoolSculpting® And #WeAllGrow Latina Network Host Discussion On The Perceptions Of Beauty And Body In The Latina Community
-
Aegon calls EUR 200 million of perpetual capital securities
-
Aegon calls EUR 200 million of perpetual capital securities
-
Ironwood Pharma (IRWD) , Allergan (AGN) Announce Settlement with Aurobindo Pharma Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation
-
Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action
-
Aegon calls USD 525 million of subordinated notes
-
Aegon calls USD 525 million of subordinated notes
-
Aegon publishes agenda for 2018 Annual General Meeting
-
Aegon publishes agenda for 2018 Annual General Meeting
-
Aegon prices USD 800 million of Tier 2 subordinated debt
-
Aegon prices USD 800 million of Tier 2 subordinated debt
-
Aegon completes sale of Aegon Ireland
-
Aegon completes sale of Aegon Ireland
-
Aegon publishes 2017 Annual Report and Review
-
Aegon publishes 2017 Annual Report and Review
-
Amgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 980 For Treatment of Three Types Of Cancer
-
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer
-
CoolSculpting® Takes to the Ice with Iconic Figure Skater Johnny Weir to Debunk Fat Loss Myths
-
Aegon Supervisory Board Member Dirk Verbeek to step down at next AGM
-
Aegon Supervisory Board Member Dirk Verbeek to step down at next AGM
-
Glenview Capital 13F Shows New Stakes in Allergan (AGN), Newell (NWL), Charter (CHTR) Aramark (ARMK) (More...)
-
Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter
-
Amgen (AMGN) and Allergan's (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC
-
European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
-
Ironwood Pharma (IRWD), Allergan (AGN) Settle with Sun Pharma Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation
-
Aegon announces significant step to capture greater operational efficiencies
-
Aegon announces significant step to capture greater operational efficiencies
-
Aegon to divest additional block of US run-off businesses
-
Aegon to divest additional block of US run-off businesses
-
Allergan (AGN) and Paratek (PRTK) Report FDA Accepted NDA For Seysara for Treatment of Moderate to Severe Acne
-
FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne
-
Aegon Completes Share Buyback Program
-
Aegon Supervisory Board Chairman Rob Routs to Step Down at Next AGM
-
Allergan (AGN) Receives FDA Clearance For CoolSculpting Treatment to Improve Appearance of Lax Tissue in Double Chin
-
Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin
-
Amgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 215 for The Treatment of Certain Types Of Cancer
-
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

